Heterologous prime-boost vaccination against H5 avian influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived H5N6 vaccine.
Hum Vaccin ImmunotherAug 5, 2026 (epub)
Esther Van Twuijver, Eve Versage, Robert L Jacobs et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II randomized controlled trial evaluated the safety and immunogenicity of an MF59-adjuvanted, cell culture-derived H5N6 vaccine in adults previously primed with an H5N1 vaccine. Results showed that primed participants had higher hemagglutination inhibition geometric mean titers against both H5N1 and H5N6 strains compared to unprimed participants, with Day 43 HI GMTs ranging from 333 to 343.
Key findings
- Primed subjects had HI GMTs of 333-343 against H5N1 on Day 43.
- Seroconversion rates exceeded 89% in primed subjects.
- Immunogenicity responses persisted to Day 202.
- No serious vaccine-related adverse events were reported.
Why it matters
The study highlights the potential of heterologous prime-boost vaccination strategies to enhance immune responses against emerging avian influenza strains, which is crucial for pandemic preparedness.